text: MOORESTOWN, N.J., Dec. 12, 2017 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare, Inc. (“TRHC”) (TRHC), a healthcare technology company advancing the field of medication safety, was named by Rock Health as the best performing IPO among digital health companies in 2017.
  The Rock Health announcement released December 4 stated: “Tabula Rasa HealthCare provides at-risk healthcare organizations technology and services to optimize medication regimens with the goal of reducing hospitalizations, lowering costs, and mitigating risk. Tabula Rasa stock is up 140% based on YTD growth, which is the largest percent increase among public digital health companies in 2017.”
  “It has been a tremendous year for TRHC in many respects,” said Chairman and CEO Calvin H. Knowlton, PhD. “Our stock has done well, indicating investors’ confidence in the company, its people, and its services. We have gained additional partners and expertise with the acquisition of Medication Therapy Management company SinfoníaRx. We also have been busy creating and deploying significant disruptive innovations, such as our recently released “Medication Risk Score”, a quick and easy way to assess which patients are at highest risk for adverse drug events (ADEs) and require medication management attention. We are pleased that these efforts have been recognized by Rock Health and their collaborators.”
  Each year, Rock Health, Fenwick & West, Goldman Sachs, and Square 1 Bank award individuals and organizations for their contribution to the digital health community and healthcare ecosystem as a whole. Honorees are celebrated for their outstanding work at a dinner ceremony to be held January 7, 2018 in San Francisco during the JP Morgan conference.
  About Tabula Rasa HealthCare, Inc.
  Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payors, providers and other healthcare organizations.
  For more information, please visit: www.TRHC.com.
  Contact:
  Media
  Dianne Semingson
  dsemingson@TRHC.com
  T: 215-870-0829
  Investors
  Bob East or Asher Dewhurst
  Westwicke Partners
  443-213-0500
  tabularasa@westwicke.com
  Tabula Rasa HealthCare to Provide Care Transition Medication Management for Tandigm Health
  MOORESTOWN, N.J. and WEST CONSHOHOCKEN, Pa., June 20, 2017 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare (TRHC), a healthcare technology company optimizing medication safety by deploying new Medication Risk Mitigation digital solutions and novel Medication Decision Support tools, and Tandigm Health, LLC, a value-based healthcare company supporting primary care physicians, announced today that Tandigm has engaged TRHC to assess the medication regimens of high-risk patients who were recently discharged from the hospital, to ensure that regimens are appropriate, effective, safe, taken as intended and have no drug interactions.
  Through TRHC’s Care Transitions services, its geriatric certified clinical pharmacists will assess the medication regimen risk by using its Medication Risk Mitigation™ platform, MedWise Advisor®, to consider all medications used prior to a hospitalization and those prescribed upon discharge. Using TRHC’s advanced technology, TRHC pharmacists will work with Tandigm physicians and their patients to streamline and individualize medication regimens. Outcomes expected to be realized from this initiative include reductions in adverse drug events (ADEs) and decreases in hospital readmission.
  “At Tandigm Health, it all starts with healthcare quality,” said Tandigm Chief Medical Officer, Kenneth Goldblum, MD, FACP. “By prioritizing medication safety and effectiveness, we can help our physicians provide the best possible care to their patients as they transfer from a hospital or rehabiltation facilitiy to their homes. We believe TRHC’s unique medication risk mitigation platform and pharmacist follow-up with each patient will help us achieve this goal, and ultimately, reduce readmissions.”
  TRHC offers the first prospective clinical solution to Medication Risk Mitigation, which is designed to increase patient safety by reducing the risk for multi-drug adverse drug events and personalizing a patient’s medication regimen. Its innovative technology platform is uniquely equipped to provide comprehensive medication risk management solutions to health plans and provider groups. TRHC’s services will further enhance Tandigm’s ability to provide network physicians with the tools and resources they need in order to deliver proactive, coordinated care.
  “TRHC is delighted to partner with Tandigm Health to provide care transition medication risk management,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “Medication safety is our highest priority. We are pleased to deploy our medication risk mitigation platform, MedWiseAdvisor®, and clinical pharmacists services, on behalf of Tandigm’s physicians and their thousands of patients.”
  The collaboration with Tandigm is an expansion of TRHC’s Care Transitions offering, which it launched earlier this year.
  About Tabula Rasa HealthCare
  Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.TRHC.com.
  About Tandigm Health
  Tandigm Health is dedicated to enhancing the ability of primary care physicians to provide the finest possible care while lowering costs through a more coordinated, proactive model. By providing greater tools and resources to its network of more than 460 physicians, Tandigm puts primary care physicians back at the center of patient care. To learn more about Tandigm’s approach to value-based health care, visit www.tandigmhealth.com.
  Micro Interventional Devices, Inc. Wins CRT 2017’s “Top Cardiovascular Innovation Award” for MIA™, Minimally Invasive Annuloplasty Technology
  World’s first annuloplasty system for mitral and tricuspid repair incorporating proprietary PolyCor™ and MyoLast™ technologies.
  NEWTOWN, Pa., March 2, 2017 /PRNewswire/ — Micro Interventional Devices, Inc™ (MID), is pleased to announce that it is the recipient of the CRT 2017 “Top Cardiovascular Innovation Award” for the company’s MIA™ technology. The award was presented to Michael Whitman, MID’s Founder, President and CEO, during the 20th annual CRT meeting on Tuesday, February 21st.
  “Receiving the 2017 ‘Top Cardiovascular Innovation Award’ at one of the world’s leading interventional cardiology conferences is an honor,” said Michael Whitman. “The promising early data from our STTAR Study in the EU indicates that our MIA technology is effective in reducing annular dimensions and tricuspid regurgitation. CRT’s recognition of the encouraging clinical results and the potential for MIA to provide an effective percutaneous solution for the treatment of tricuspid and mitral valve disease is a tremendous accomplishment for our team.”
  The MIA technology is designed to reduce annular dimensions and regurgitation during percutaneous transcatheter mitral and tricuspid repair. The annular reduction is achieved without sutures or other intervention due to the compliant, self-tensioning MIA implant incorporating the company’s proprietary PolyCor™ anchors and MyoLast™ implantable elastomer.
  About Micro Interventional Devices, Inc. (MID):
  MID is the world leader in percutaneous transcatheter compliant fixation technology addressing unmet needs in structural heart disease.
  Company Contact:
  Micro Interventional Devices, Inc.
  Katherine Whitman
  Product Director
  215 600 1270
  info@microinterventional.com
  www.microinterventional.com
  Two Portfolio Companies Named to Deloitte 2016 North America Technology Fast 500™ Rankings
  FSAStore.com #156 and CMC #484 **Click here to view complete list**
  SAN FRANCISCO, Nov. 16, 2016—Deloitte today released the 2016 Technology Fast 500, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences, and energy tech sectors. Loot Crate claimed the top spot with a growth rate of 66,661 percent from 2012 to 2015.
  Based in Los Angeles, Loot Crate delivers monthly curated mystery boxes of entertainment and pop culture themed collectibles to fans. Founded in 2012, Loot Crate has more than 650,000 subscribers worldwide in 35 countries. Loot Crate’s position at the top of this year’s list showcases how innovation isn’t always about new technology and invention, but also about ingenuity, the recombining of existing assets, and know-how in new ways to maximize value.
  Awardees are selected for this honor based on percentage fiscal year revenue growth from 2012 to 2015. Overall, 2016 Technology Fast 500 companies achieved revenue growth ranging from 121 percent to 66,661 percent in the 2012 to 2015 time frame, with a median growth of 290 percent.
  “Our personal and professional lives are shifting in response to new technologies and business models that are changing the way we work and live,” said Sandra Shirai, principal, Deloitte Consulting LLP and US Technology, Media, and Telecommunications leader. “The 2016 Technology Fast 500 winners are supporting this shift by creating experiences for their customers, surpassing expected possibilities, and helping to envision even more effective and ingenious solutions. Loot Crate is just one example of how effective organizations face disruption with confidence, striving to understand and harness the potential to propel forward. That means taking risks, encouraging experimentation, and embracing transformation.”
  “Being recognized by Deloitte as the fastest growing technology company on the Fast 500 List is an incredible honor,” said Chris Davis, CEO and co-founder of Loot Crate. “Our desire to curate unique experiences for our customers through our shared passion for pop culture, games, and entertainment brands gives our fan commerce business a sense of purpose as we scale and makes coming to work a lot of fun.”
  The top 10 ranked companies are as follows:
  2016 Rank
  Company
  Sector
  Revenue growth (2012 to 2015)
  City, State
  1
  Loot Crate Digital content/
  media/entertainment 66,661 percent Los Angeles, California
  2
  Yieldbot Digital content/
  media/entertainment 39,783 percent New York, New York
  3
  ARIAD Pharmaceuticals, Inc. Biotechnology/pharmaceutical 21,191 percent Cambridge, Massachusetts
  4
  SearchMarketers.com. Digital content/
  media/entertainment 16,547 percent Irvine, California
  5
  BounceX Software 14,575 percent New York, New York
  6
  Doximity Software 14,350 percent San Jose, California
  7
  Gainsight Software 12,730 percent Redwood City, California
  8
  Lexicon Pharmaceuticals Inc. Biotechnology/pharmaceutical 11,839 percent The Woodlands, Texas
  9
  Datadog Software 10,303 percent New York, New York
  10
  AppLovin Software 10,276 percent Palo Alto, California
  Regional innovation remains strong
  Deloitte’s Technology Fast 500 winners hail from cities far and wide across North America—from Los Angeles to New York to Canada. Of the dozens of locations represented on the list, some have a particularly strong track record of turning out successful, fast growing companies that are releasing new, emerging technologies.
  Silicon Valley, well-known as an innovation hot spot, continues to lead in representation with 20 percent of the companies on the list, 63 percent of which are in the software industry. The New York Metro area and the Greater Los Angeles area came in next, with 17 and 8 percent respectively of companies on the list in software and digital content, and the media and entertainment sectors. Rounding out the top five markets, the District of Columbia dominated in software and New England in software and biotech.
  Following is a list of innovative cities with a significant concentration of winners:
  Location
  Percenage of list
  Fastest-growing company in the region
  Overall company ranking
  Dominate sectors in location
  San Francisco Bay Area
  20 percent Doximity 7 Software 63 percent
  New York Metro Area
  17 percent Yieldbot 2 Software 47 percent; digital content/media/entertainment 25 percent
  Greater Los Angeles Area
  8 percent Loot Crate 1 Software 49 percent; digital/ content/media entertainment 27 percent
  Washington, DC
  6 percent Supernus Pharmaceuticals, Inc. 12 Software 63 percent
  New England
  5 percent ARIAD Pharmaceuticals, Inc. 3 Software 44 percent; biotech 33 percent
  Software companies maintain 21-year stronghold
  Software continues to have the greatest impact across technology sectors, representing 58 percent of the entire list and five of the top 10 winners overall. Of the private companies, 44 percent identified themselves in software as a service (SaaS), 24 percent in enterprise software, and 10 percent in security. Since the creation of the ranking, each year software companies have made up the majority of winners, with a median growth rate of 275 percent this year.
  Furthermore, biotechnology/pharmaceutical companies make up the second-most prevalent sector in this year’s rankings, comprising 13 percent of the Technology Fast 500. Digital content, media, and entertainment companies follow next with 12 percent of companies representing this year’s list and a median growth rate of 544 percent.
  The percentage of companies from industry sectors represented on the Technology Fast 500 are as follows:
  Sector
  Percentage
  Sector leader
  Median revenue growth (2012 to 2015)
  Software
  58 percent BounceX 275 percent
  Biotechnology/pharmaceutical
  13 percent ARIAD Pharmaceuticals, Inc. 428 percent
  Digital content/media/entertainment
  12 percent Loot Crate 544 percent
  Medical devices
  5 percent Strata Skin Sciences, Inc. 255 percent
  Communications/networking
  5 percent MacStadium, Inc. 199 percent
  Electronic devices/hardware
  4 percent FORM Holdings Corp. 290 percent
  Semiconductor
  2 percent Movidius 209 percent
  Energy tech
  1 percent Norbachi 215 percent
  Majority of companies received venture backing
  In the 2016 rankings, 68 percent of the companies were backed by venture capitalists at some point in their company history. Notably, eight of the top 10 companies on the Technology Fast 500 received venture funding.
  “Investors continue to remain confident in North American technology companies. Companies that enhance efficiencies through new technologies, enter new markets, and develop new products and business models are the ones who sustain fundraising and will provide a significant return on investment. These are the rising stars,” said Jim Atwell, partner, Deloitte & Touche LLP, and national managing partner of the Emerging Growth Company practice. “The industry understands that while innovation entails taking risks, the absence of innovation is riskier. This is something the Technology Fast 500 winners recognize as they continue to grow and move their companies forward.”
  For additional details on the Technology Fast 500, including the complete list and qualifying criteria, visit www.fast500.com. Connect with us on Twitter: @DeloitteTMT; #Fast500.
  About Deloitte’s Technology, Media and Telecommunications practice
  Deloitte’s Technology, Media, & Telecommunications (TMT) practice provides industry-leading audit, consulting, tax, and advisory services to more than 1,800 clients in the United States, including the vast majority of market category leaders across all sector segments. Deloitte practitioners, many with direct industry experience, work with one purpose: to deliver measurable, lasting results. They help reinforce public trust in our capital markets, inspire clients to make their most challenging business decisions with confidence, and help lead the way toward a stronger economy and a healthy society. TMT clients count on Deloitte to help them transform uncertainty into a possibility and rapid change into lasting progress. Deloitte practitioners know how to anticipate, collaborate, and innovate, and create opportunity from even the unforeseen obstacle.
  About Deloitte
  Deloitte provides industry-leading audit, consulting, tax, and advisory services to many of the world’s most admired brands, including 80 percent of the Fortune 500. Our people work across more than 20 industry sectors to deliver measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to make their most challenging business decisions with confidence, and help lead the way toward a stronger economy and a healthy society.
  Tabula Rasa HealthCare Announces Third Quarter 2016 Operating Results
  MOORESTOWN, N.J., Nov 09, 2016 (GLOBE NEWSWIRE via COMTEX) —
  Tabula Rasa HealthCare, Inc. (“TRHC”) TRHC, +4.66% a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, today announced its financial results for the third quarter ended September 30, 2016.
  TRHC Chairman and CEO, Calvin H. Knowlton, Ph.D., commented, “I’m pleased with our performance during our first publically reported quarter. We continue to win new business within our core market, PACE (Program of All-Inclusive Care for the Elderly, a Medicare Advantage-type plan), as well as successfully expand our Medication Risk Mitigation platform into adjacent markets with other types of health plans, further proving its scalability.”
  Dr. Knowlton continued, “There is significant runway ahead of us as we continue to develop and evolve our proprietary Medication Risk Mitigation platform and address larger patient populations with our goal of improving outcomes and lowering healthcare cost.”
  Financial Performance for the Three Months Ended September 30, 2016
  All comparisons, unless otherwise noted, are to the three months ended September 30, 2015.
  Total revenue was $24.2 million, an increase of 35%. Total revenue included product revenue of $20.7 million, an increase of 35%, and service revenue of $3.4 million, an increase of 34%.
  Gross margin was 29%, compared to 32%. The year over year decline is primarily related to a mix shift in client and business make-up, as well as to staffing increases associated with upcoming contracts.
  Net loss was $142 thousand, compared to a net loss of $3.3 million. Third quarter 2016 included a $1.4 million expense related to the early extinguishment of debt.
  Net loss per diluted share was $0.08, compared to a net loss per share of $3.21. The net loss per share calculations were based on a diluted share count of 10.3 million for the third quarter of 2016, compared to 4.4 million shares a year ago.
  Non-GAAP Adjusted EBITDA was $3.3 million, compared to $2.4 million, an increase of 38% compared to a year ago. Adjusted EBITDA margin of 13.5% in the third quarter of 2016 compared favorably to 13.2% during the same period in 2015.
  Non-GAAP Adjusted net income per diluted share was $0.06, compared to a net loss per share of $0.01.
  A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. Non-GAAP results exclude change in fair value of warrant liability, loss on extinguishment of debt, change in fair value of acquisition-related contingent consideration (income) expense and stock-based compensation expense. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.
  Business Outlook
  Fourth Quarter 2016 Guidance: Revenue for TRHC’s fourth quarter 2016 is expected to be in the range of $25 million to $26 million. Net loss is expected to be in the range of $6 million to $7 million. Net loss projections include approximately $5 million of expense related to the extinguishment of debt associated with the early repayment of a credit facility in connection with TRHC’s initial public offering, as well as stock based compensation expense of approximately $3.5 million related to restricted stock grants and shares issued in connection with the initial public offering. Adjusted EBITDA is expected to be in the range of $3.5 million to $4.0 million.
  Full Year 2016 Guidance: Revenue for fiscal year 2016 is expected to be in the range of $92 million to $93 million. Net loss is expected to be in the range of $6 million to $7 million. Net loss projections include approximately $6.4 million of expense related to the extinguishment of debt, as well as stock based compensation expense of approximately $3.6 million related to restricted stock grants and shares issued in connection with the initial public offering. Adjusted EBITDA is expected to be in the range of $12.5 million to $13.0 million.
  TRHC has not provided a reconciliation of projected GAAP Net Income to Adjusted EBITDA guidance because estimates of certain reconciling items cannot be provided without unreasonable effort. Our Adjusted EBITDA guidance for the year ending December 31, 2016, assumes anticipated losses of $6.4 million related to the extinguishment of debt, income of $0.6 million related to the remeasurement of our warrant liability, projected stock compensation of $4.2 million, projected depreciation and amortization charges of $5.1 million and interest expense of $4.5 million. In addition, we assume $0.4 million of income tax expense related to indefinite-lived deferred tax liabilities for goodwill amortization. We cannot provide a reliable forward-looking estimate of certain other reconciling items because they are either event-driven or difficult to quantify without unreasonable effort, in particular the revaluation of our contingent consideration.
  Tabula Rasa Healthcare to Announce Third Quarter 2016 Operating Results and Host Conference Call on Wednesday, November 9, 2016
  MOORESTOWN, N.J., Oct. 26, 2016 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare, Inc.(NASDAQ:TRHC), a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, will release its third quarter 2016 operating results on Wednesday, November 9, 2016 after market close, with a conference call to follow at 5:00 p.m. EDT.
  Stockholders and interested participants may listen to a live broadcast of the conference call by dialing 844-413-0947 or 216-562-0423 for international callers, and referencing participant code 98688454 approximately 15 minutes prior to the call. A live webcast of the conference call will be available on the investor relations section of the company’s web site and an audio file of the call will also be archived for 90 days at ir.trhc.com. After the conference call, a replay will be available until December 9, 2016 and can be accessed by dialing 855-859-2056 or 404-537-3406 for international callers, and referencing participant code 98688454.
  About Tabula Rasa HealthCare
  Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.tabularasahealthcare.com.
  Contact:
   
  Investors
  Bob East or Asher Dewhurst
  Westwicke Partners
  443-213-0500
  tabularasa@westwicke.com
   
  Media
  Dianne Semingson
  dsemingson@TRHC.com
  215-870-0829
  Tabula Rasa Healthcare, Inc.
  Tabula Rasa HealthCare Announces Pricing of Initial Public Offering
  MOORESTOWN, N.J., Sept. 28, 2016 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare, Inc.(NASDAQ:TRHC), a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, today announced the pricing of its initial public offering of 4,300,000 shares of its common stock, at a price of $12.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Tabula Rasa. The shares are expected to begin trading on The NASDAQ Global Market on September 29, 2016, under the symbol “TRHC.” In addition, Tabula Rasa granted the underwriters a 30-day option to purchase up to 645,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. This offering is expected to close on October 4, 2016, subject to customary closing conditions.
  Wells Fargo Securities and UBS Investment Bank are acting as joint-book running managers for the offering. Piper Jaffray is also acting as a book-runner, with Baird and Stifel acting as co-managers for the offering.
  A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on September 28, 2016. The offering will be made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to this offering, when available, may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov, or alternatively, from: Wells Fargo Securities, LLC by mailing: Attention: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, by email: cmclientsupport@wellsfargo.com or by Telephone: (800) 326-5897, or from UBS Securities LLC by mailing: Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019 or by Telephone: (888) 827-7275.
  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
  Contact
  Bob East or Asher Dewhurst
  Westwicke Partners
  443-213-0500
  tabularasa@westwicke.com
  TB Biosciences, Inc. Closes $1.5 Million in Series A Financing
  Proceeds to Develop a Novel Point-of-Care Diagnostic Test for Active Tuberculosis
  Bethlehem, Pa – July 18, 2013 – Tuberculosis has been all but eradicated in the United States, yet is a massive killer worldwide, especially in developing countries. Currently, over 90 million sputum tests are conducted annually. The sputum test is less than 50% accurate and unable to diagnose many with active tuberculosis. With results no better than a coin toss, the World Health Organization (WHO) in 2011 recommended the use of ALL existing serological tests be discontinued. “The goal of TB Biosciences is to develop an accurate, easy to use, affordable, rapid point-of-care test to detect active tuberculosis and replace the unreliable sputum smear,” said Sam Niedbala, Ph.D., CEO and co-founder of TB Biosciences.
  TB Biosciences, Inc., a development-stage company, announced today that it secured $1.5 million in Series A financing. The funding was led by Originate Ventures and included Ben Franklin Technology Partners of Northeastern Pennsylvania and the NYU Innovation Venture Fund. Together with recent funding from the National Institute of Health, (NIH), total new funds available for the project are in excess of $2.5 million. The funding will be used to support product development and clinical trials.
  Dr. Niedbala continues, “TB Biosciences uses key peptides to detect antibodies in patients with active tuberculosis derived from the genome of the tuberculosis organism, thus offering a completely new approach to testing. Careful screening of expressed proteins has unlocked a powerful library of critical peptides, which will enable the Company to target those with active tuberculosis in children, adults and those co-infected with HIV. Preliminary performance data using samples from endemic countries has resulted in sensitivity greater than 90%. This novel approach was developed over the past 20 years at New York University School of Medicine under the scientific leadership of Suman Laal, Ph.D.”
  “Sam Niedbala was a co-founder and the Chief Science Officer at OraSure Technologies (NASDAQ:OSUR) during the time that OraSure commercialized the first FDA-approved rapid, oral fluid and blood HIV test. He has extensive experience developing rapid infectious disease tests, and I believe that we have a unique opportunity under his leadership to revolutionize the way tuberculosis testing is done in the future,” stated Mike Gausling, Managing Partner at Originate Ventures. “Sam is assembling a world-class team to commercialize the technology, and Originate Ventures is excited to help TB Biosciences deliver that promise.”
  “The early sensitivity and specificity data in the lab has demonstrated that TB Biosciences’ tuberculosis test is expected to meet or exceed consensus targets for sensitivity and specificity once the test is optimized. This would be a major breakthrough in tuberculosis testing and could go a long way to saving many lives each year,” says Frank Rimalovski, Executive Director of the NYU Innovation Venture Fund.
  “The product development efforts for the tuberculosis test will occur in Bethlehem, Pa, and we are excited to be investors in TB Biosciences under Sam’s leadership,” stated Chad Paul, President and Chief Executive Officer of the Ben Franklin Technology Partners of Northeastern Pennsylvania. “Over the past 20 years, Sam Niedbala and Mike Gausling have created a proven track record of building a Russell 2000 company from scratch starting in our business incubator in 1988. The opportunity to invest in TB Biosciences is a terrific opportunity for us and for our global community.”
  About TB Biosciences
  TB Biosciences, Inc. is an early stage development medical diagnostics company founded in June 2013 to develop a rapid point-of-care tuberculosis test that meets performance standards around the world. The goal of TB Biosciences is to commercialize a simple to operate and use tuberculosis test that replaces the 125 year old sputum smear test. The Company is using an array of patented peptides developed and exclusively licensed from the NYU School of Medicine. To learn more, visit www.TBBiosciences.com.
  About Originate Ventures
  Originate Ventures is a venture capital investment firm, targeting early stage product and services companies located in Pennsylvania and the Mid-Atlantic region. The firm focuses on opportunities with medical devices, healthcare, consumer, information technology, Web-based and commercial products. Operating with an entrepreneurial spirit and vision, Originate’s investments range in size from $500,000 to $4,000,000. For more information, visit www.originateventures.com.
  About NYU Innovation Venture Fund
  The NYU Innovation Venture Fund is a $20 million seed stage venture capital fund created in 2010 to invest in startups founded by, and/or commercializing technologies developed by NYU students, faculty and researchers. For more information, visit nyu.edu/venturefund.
  About the Ben Franklin Technology Partners of Northeastern Pennsylvania
  The Ben Franklin Technology Partners of Northeastern Pennsylvania creates and retains highly paid, sustainable jobs by linking early-stage technology-based firms and established manufacturers with experts, universities, funding, and other resources to help them prosper through innovation. The Ben Franklin Technology Partners has returned $3.60 to the Pennsylvania treasury for every $1.00 invested in the program. It is part of an award-winning, four-center economic development initiative of the Pennsylvania Department of Community and Economic Development, and is funded by the Ben Franklin Technology Development Authority. For more information, visit www.nep.benfranklin.org.
  # # #
  Contact:
  R. Sam Niedbala, Ph.D.
  Chief Executive Officer
  TB Biosciences, Inc.
  T: 800-822-9923 Ext. 1
  www.TBBiosciences.com
  BA Insight Closes Latest Round of Venture Funding
  Funding Fuels Sustained Growth and Resource Expansion as Demand for Search-Based Applications Increases Across the Enterprise
  New York, NY– April 3, 2013 – BA Insight today announced that it has secured its latest round of funding, raising $4.5 million, bringing the total amount raised to date to $15.7 million. All four of the company’s current venture capital investors participated in the round including Milestone Venture Partners, Osage Venture Partners, Paladin Capital Group and Originate Ventures. The funding supports the company’s growth as the market continues to drive demand for solutions that unlock data across the enterprise.
  BA Insight’s advanced search technology redefines how people access siloed information and collaborate. Organizations are increasingly dealing with rapidly growing volumes of structured and unstructured data, the inability to integrate information from legacy systems, and the move of many organizational systems to the cloud. As a result they often lack insight into critical business information. BA Insight enables enterprises to bring this information together for users, giving them actionable insights into customers, products, projects, expertise and more.
  “Enterprise search is broken,” said Philip Eliot, Principal at Paladin Capital Group, “and BA Insight is unique in its ability to deliver useful information to the enterprise regardless of where, when and how they need it. Their solutions revolutionize information access.”
  “Our continued investment in BA Insight reflects our confidence in the ability of BA Insight’s platform to transform search into a powerful weapon for the enterprise,” said Todd Pietri, co-founder and General Partner of Milestone Venture Partners. “BA Insight delivers tools that enable organizations to leverage their investments in existing solutions and expose data in an actionable, relevant way.”
  BA Insight customers include industry-leading companies across a variety of industries including the legal, oil and gas, and pharmaceutical/life sciences. For more information on products and services, visit www.bainsight.com.
  About BA Insight
  BA Insight™ is the leading provider of integrated search technologies that help organizations leverage the full power of Microsoft SharePoint® across the enterprise. BA Insight’s flagship Longitude Search and Longitude Connector products let organizations extend Microsoft’s enterprise search capabilities across dozens of CRM, ERP, ECM, messaging, and collaboration systems, and delivers rich document preview and assembly tools that empower knowledge workers to act upon search results with greater speed and effectiveness.
  About Milestone Venture Partners
  Milestone Venture Partners is a venture capital fund located in New York City with $100 million under management. Milestone specializes in early-stage software and data services investments in Greater New York. Areas of expertise include enterprise information technology, Digital Health, media, marketing services and FinTech. For more information, visit www.milestonevp.com.
  About Originate Ventures
  Originate Ventures is a venture capital investment firm, targeting early stage product and services companies located in Pennsylvania and the Mid-Atlantic region. The firm focuses on opportunities with medical devices, healthcare, consumer, information technology, Web-based and commercial products. Operating with an entrepreneurial spirit and vision, Originate’s investments range in size from $500,000 to $4,000,000. For more information, visit www.originateventures.com.
  About Osage Venture Partners
  Osage Venture Partners (OVP) is a venture capital firm located just outside of Philadelphia, Pennsylvania, that invests in early-stage enterprise technology companies in the Mid-Atlantic region. OVP raised its first fund in 2005, and has invested almost exclusively in enterprise software companies since that time. With over $100M under management, OVP seeks to invest in determined and creative entrepreneurs and provide them with the assistance required to build high growth businesses. For more information, visit www.osagepartners.com.
  About Paladin Capital Group
  Paladin Capital Group is a leading multi-stage private equity firm providing capital and strategic guidance to growing companies in the IT, telecommunications and alternative energy sectors. The firm focuses on companies with products and services that are “dual use” in nature, serving both commercial and government customers. Paladin has over $950 million dollars of committed capital across multiple funds and has invested in over 50 portfolio companies. For more information, visit www.paladincapgroup.com.
  For information, contact:
  Laura Sankowich
  VP of Marketing at BA Insight
  lsankowich@bainsight.com
  646-786-8562
  Rachel Holmes
  Corporate Communications Manager at BA Insight
  rholmes@bainsight.com
  646-786-8556
  Micro Interventional Devices, Inc. Closes First Tranche of $5 Million Series B Financing
  Proceeds to Fund Enhancement and CE Mark Approval of the Permaseal(TM) Transapical Access and Closure Technology
  Bethlehem, PA – January 14, 2013 – Micro Interventional Devices, Inc.™ (MID), an emerging cardiovascular medical device company, announced today it has secured $3.5 million of its expected $5 million Series B financing. The initial tranche was led by Originate Ventures with existing investor, Battelle Ventures, LP, also participating in the round. In conjunction with the financing Mike Gausling, Managing Partner of Originate Ventures, will join the MID Board of Directors.
  The funding will be used to support the ongoing development of the Permaseal™ product, advance the STASIS clinical study (Sutureless Transapical Access and Closure Study) and obtain CE Mark approval for Permaseal. The funding will also support MIDʼs research and development initiatives focused on developing its percutaneous transapical and large bore femoral access and closure devices.
  “The market for transcatheter aortic valve implantation is expected to grow rapidly over the next several years as innovation continues to improve and simplify the procedure,” said Mike Gausling, Managing Partner of Originate Ventures. “Originate Ventures believes that Permaseal represents a significant opportunity given these market dynamics. I am excited to be joining MIDʼs Board of Directors and to work with management to ensure the successful clinical and commercial development of this revolutionary access and closure technology.”
  Permaseal is the first transapical access device to enable true “self-sealing,” sutureless cardiac access and closure. The device is designed to enable a range of structural heart repair procedures including transcatheter aortic valve implantation (TAVI) and mitral valve replacement and repair.
  “Closing the first tranche in our Series B, and the addition of Mike Gausling to MIDʼs Board, are key milestones in the growth of MID and ongoing development of Permaseal,” stated Michael Whitman, President and CEO of MID. “As TAVI becomes more widespread there is a critical need for efficient cardiac access and closure devices. We believe the Permaseal platform is a true game-changing technology, and we look forward to completing the STASIS trial and securing CE Mark in order to fulfill this unmet therapeutic need.”
  About Micro Interventional Devices, Inc:
  Micro Interventional Devices, Inc. (MID) is an emerging cardiovascular medical device company founded in May 2010. MID is developing solutions for transcatheter aortic valve implantation (TAVI), transcatheter mitral valve replacement and repair and other emerging structural heart repair procedures. The company is developing proprietary technology based on a breakthrough in soft-tissue anchoring and associated delivery devices that enable off-pump procedures. To learn more, please visit www.microinterventional.com.
  Company Contact:
  Micro Interventional Devices, Inc.
  Katherine Whitman
  Marketing Communications Manager
  kwhitman@microinterventional.com
  Media Contact:
  Tiberend Strategic Advisors, Inc.
  (212) 827-0020
  Claire Sojda
  csojda@tiberend.com
  Page 2 of 3«123»
  Portfolio News
  FDA Grants Micro Interventional Devices, Inc. Breakthrough Device Designation for the MIA™-T Percutaneous Tricuspid Annuloplasty System: NEWTOWN, Pa., May 27, 2021 /PRNewswire/ -- Micro Interventional Devices (MID) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its MIA™-T Percutaneous Tricuspid...
  Katabat Attracts Significant Growth Investment from Tritium Partners and Terminus Capital Partners: News provided by Tritium Partners; Terminus Capital Partners Aug 05, 2020, 13:00 ET WILMINGTON, Del., Aug. 5, 2020 /PRNewswire/ -- Katabat, a leading global provider of debt management software...
  TRHC Fills the Information Gap on COVID-19 Proposed Therapies with a New Digital Resource: Moorestown, NJ, May 19, 2020 – Tabula Rasa HealthCare® Corporation (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today published on the web the TRHC COVID-19 Treatment...
  BA INSIGHT RECOGNIZED AS CHARTER MEMBER OF THE MICROSOFT CONTENT SERVICES PARTNER PROGRAM: BOSTON, MA – May 5, 2020 – BA Insight, a leading provider of internet-like search for enterprises, is pleased to announce its recognition from Microsoft as a Charter Member of the...
  ENCOURAGING RESIDENTS TO SWITCH TO ELECTRONIC PAYMENTS IS CRITICAL IN THE TIME OF COVID-19: April 27, 2020 -- COVID-19’s greatest continuity challenge for payments is the handling and processing of paper checks. Whether residents drop checks at on-site offices or mail checks to...
  Copyright © 2020 Originate Ventures. All rights reserved. Originate Ventures is a licensee of Originate.